Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2018-09-12

Clinical Trial Update: Phase 3 Study of M923 and Humira® in Subjects With Chronic Plaque-type Psoriasis [Phase 3]

View source ↗

Summary

Phase 3 trial update for M923 in combination with Humira in chronic plaque-type psoriasis; study completed with results posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Humira (adalimumab)
  • M923

Snippet

Sponsor: Momenta Pharmaceuticals, Inc. | Conditions: Chronic Plaque Psoriasis, Psoriasis | Phase 3 | Status: COMPLETED | Results posted: 2018-09-12